Phospholipase C{beta}3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 19066214.
- Also identified by DOI 10.1073/pnas.0810899105 and PMC identifier 2604939.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment of neuropathic pain is a major clinical problem. This study shows expression of phospholipase ss3 (PLCss3) in mouse and human DRG neurons, mainly in small ones and mostly with a nonpeptidergic phenotype. After spared nerve injury, the pain threshold was strongly reduced, and systemic treatment of such animals with the unselective PLC inhibitor U73122 caused a rapid and long-lasting (48-h) increase in pain threshold. Thus, inhibition of PLC may provide a way to treat neuropathic pain.
Medical subject headings
- Estrenes
- Hyperalgesia
- Pain
- Phosphodiesterase Inhibitors
- Phospholipase C beta
- Pyrrolidinones
- Spinal Cord Injuries